Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Altimmune, Inc. stock logo
ALT
Altimmune
$5.51
-3.5%
$5.11
$3.55
$11.16
$446.90M1.132.81 million shs2.41 million shs
Mereo BioPharma Group plc stock logo
MREO
Mereo BioPharma Group
$2.18
-2.7%
$2.27
$1.58
$5.02
$346.62M0.531.12 million shs778,260 shs
Zura Bio Limited stock logo
ZURA
Zura Bio
$1.00
-2.0%
$1.24
$0.97
$5.56
$68.38M0.05409,539 shs565,550 shs
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
$8.45
-2.3%
$7.62
$4.20
$9.76
$462.05M1.87642,157 shs494,565 shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Altimmune, Inc. stock logo
ALT
Altimmune
-3.50%-5.81%+8.68%-7.24%-24.83%
Mereo BioPharma Group plc stock logo
MREO
Mereo BioPharma Group
-2.68%-5.22%-12.80%-11.02%-26.10%
Zura Bio Limited stock logo
ZURA
Zura Bio
-1.96%-6.54%-27.01%-19.35%-81.79%
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
-2.31%-1.86%+17.36%+14.34%+81.33%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Altimmune, Inc. stock logo
ALT
Altimmune
2.3928 of 5 stars
3.51.00.00.02.63.30.6
Mereo BioPharma Group plc stock logo
MREO
Mereo BioPharma Group
2.1126 of 5 stars
3.62.00.00.03.21.70.0
Zura Bio Limited stock logo
ZURA
Zura Bio
2.6562 of 5 stars
3.62.00.00.03.22.50.6
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
3.3221 of 5 stars
4.62.00.00.03.51.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Altimmune, Inc. stock logo
ALT
Altimmune
3.00
Buy$20.20266.61% Upside
Mereo BioPharma Group plc stock logo
MREO
Mereo BioPharma Group
3.25
Buy$7.71253.87% Upside
Zura Bio Limited stock logo
ZURA
Zura Bio
3.13
Buy$14.331,333.33% Upside
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
3.11
Buy$22.29163.74% Upside

Current Analyst Ratings Breakdown

Latest ZURA, ZVRA, MREO, and ALT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/14/2025
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
5/14/2025
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$25.00 ➝ $25.00
5/13/2025
Mereo BioPharma Group plc stock logo
MREO
Mereo BioPharma Group
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
5/9/2025
Zura Bio Limited stock logo
ZURA
Zura Bio
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$19.00 ➝ $17.00
4/9/2025
Mereo BioPharma Group plc stock logo
MREO
Mereo BioPharma Group
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
4/3/2025
Zura Bio Limited stock logo
ZURA
Zura Bio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
4/3/2025
Altimmune, Inc. stock logo
ALT
Altimmune
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
4/3/2025
Zura Bio Limited stock logo
ZURA
Zura Bio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$5.00 ➝ $3.00
3/27/2025
Mereo BioPharma Group plc stock logo
MREO
Mereo BioPharma Group
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$7.00
3/26/2025
Zura Bio Limited stock logo
ZURA
Zura Bio
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$20.00 ➝ $19.00
3/26/2025
Mereo BioPharma Group plc stock logo
MREO
Mereo BioPharma Group
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Altimmune, Inc. stock logo
ALT
Altimmune
$20K22,344.98N/AN/A$2.75 per share2.00
Mereo BioPharma Group plc stock logo
MREO
Mereo BioPharma Group
$1M346.62N/AN/A$0.36 per share6.06
Zura Bio Limited stock logo
ZURA
Zura Bio
N/AN/AN/AN/A$1.85 per shareN/A
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
$40.59M11.38N/AN/A$1.71 per share4.94
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Altimmune, Inc. stock logo
ALT
Altimmune
-$88.45M-$1.26N/AN/AN/A-199,076.92%-55.81%-50.60%8/6/2025 (Estimated)
Mereo BioPharma Group plc stock logo
MREO
Mereo BioPharma Group
-$29.47M-$0.07N/AN/AN/AN/AN/AN/A8/12/2025 (Estimated)
Zura Bio Limited stock logo
ZURA
Zura Bio
-$69.24M-$0.70N/AN/AN/AN/A-37.36%-29.81%8/12/2025 (Estimated)
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
-$46.05M-$1.90N/A42.25N/A-342.63%-159.54%-51.50%8/12/2025 (Estimated)

Latest ZURA, ZVRA, MREO, and ALT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Altimmune, Inc. stock logo
ALT
Altimmune
-$0.35-$0.26+$0.09-$0.26$0.00 million$0.01 million
5/13/2025Q1 2025
Mereo BioPharma Group plc stock logo
MREO
Mereo BioPharma Group
-$0.01-$0.02-$0.01-$0.02$72.50 millionN/A
5/13/2025Q1 2025
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
-$0.21-$0.06+$0.15-$0.06$16.96 million$20.40 million
5/8/2025Q1 2025
Zura Bio Limited stock logo
ZURA
Zura Bio
-$0.17-$0.19-$0.02-$0.19N/AN/A
3/26/2025Q4 2024
Mereo BioPharma Group plc stock logo
MREO
Mereo BioPharma Group
$0.02-$0.01-$0.03-$0.01$72.50 millionN/A
3/25/2025Q4 2024
Zura Bio Limited stock logo
ZURA
Zura Bio
-$0.17-$0.08+$0.09-$0.08N/A$0.00 million
3/11/2025Q4 2024
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
-$0.39-$0.67-$0.28-$0.67$8.93 million$12.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Altimmune, Inc. stock logo
ALT
Altimmune
N/AN/AN/AN/AN/A
Mereo BioPharma Group plc stock logo
MREO
Mereo BioPharma Group
N/AN/AN/AN/AN/A
Zura Bio Limited stock logo
ZURA
Zura Bio
N/AN/AN/AN/AN/A
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Altimmune, Inc. stock logo
ALT
Altimmune
N/A
16.87
16.87
Mereo BioPharma Group plc stock logo
MREO
Mereo BioPharma Group
N/A
6.10
6.10
Zura Bio Limited stock logo
ZURA
Zura Bio
N/A
10.36
10.36
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
0.84
2.88
2.88

Institutional Ownership

CompanyInstitutional Ownership
Altimmune, Inc. stock logo
ALT
Altimmune
78.05%
Mereo BioPharma Group plc stock logo
MREO
Mereo BioPharma Group
62.83%
Zura Bio Limited stock logo
ZURA
Zura Bio
61.14%
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
35.03%

Insider Ownership

CompanyInsider Ownership
Altimmune, Inc. stock logo
ALT
Altimmune
4.10%
Mereo BioPharma Group plc stock logo
MREO
Mereo BioPharma Group
5.50%
Zura Bio Limited stock logo
ZURA
Zura Bio
14.23%
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
2.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Altimmune, Inc. stock logo
ALT
Altimmune
5081.11 million68.21 millionOptionable
Mereo BioPharma Group plc stock logo
MREO
Mereo BioPharma Group
40159.00 million148.74 millionOptionable
Zura Bio Limited stock logo
ZURA
Zura Bio
368.38 million50.86 millionOptionable
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
2054.68 million52.10 millionOptionable

Recent News About These Companies

Zevra Therapeutics (NASDAQ:ZVRA) Upgraded at Wall Street Zen
Research Analysts Offer Predictions for ZVRA Q2 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Altimmune stock logo

Altimmune NASDAQ:ALT

$5.51 -0.20 (-3.50%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$5.52 +0.02 (+0.27%)
As of 04:22 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Mereo BioPharma Group stock logo

Mereo BioPharma Group NASDAQ:MREO

$2.18 -0.06 (-2.68%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$2.25 +0.07 (+3.17%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.

Zura Bio stock logo

Zura Bio NASDAQ:ZURA

$1.00 -0.02 (-1.96%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$1.04 +0.04 (+4.00%)
As of 04:35 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.

Zevra Therapeutics stock logo

Zevra Therapeutics NASDAQ:ZVRA

$8.45 -0.20 (-2.31%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$8.41 -0.04 (-0.49%)
As of 04:11 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.